These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 35872608)
1. Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor poly-agonists: a new era in obesity pharmacotherapy. Malik IO; Petersen MC; Klein S Obesity (Silver Spring); 2022 Sep; 30(9):1718-1721. PubMed ID: 35872608 [TBL] [Abstract][Full Text] [Related]
2. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Fisman EZ; Tenenbaum A Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089 [TBL] [Abstract][Full Text] [Related]
3. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Frías JP Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes. De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793 [TBL] [Abstract][Full Text] [Related]
5. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'. Skow MA; Bergmann NC; Knop FK Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961 [TBL] [Abstract][Full Text] [Related]
6. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents. Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027 [TBL] [Abstract][Full Text] [Related]
8. GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy. Lafferty RA; Flatt PR; Irwin N Expert Opin Pharmacother; 2023 Apr; 24(5):587-597. PubMed ID: 36927378 [TBL] [Abstract][Full Text] [Related]
9. [A new era for glucagon-like peptide-1 receptor agonists]. Neuville MF; Paquot N; Scheen AJ Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066 [TBL] [Abstract][Full Text] [Related]
10. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Nauck MA; D'Alessio DA Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763 [TBL] [Abstract][Full Text] [Related]
11. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097 [TBL] [Abstract][Full Text] [Related]
12. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence. Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652 [TBL] [Abstract][Full Text] [Related]
13. The incretin/glucagon system as a target for pharmacotherapy of obesity. Del Prato S; Gallwitz B; Holst JJ; Meier JJ Obes Rev; 2022 Feb; 23(2):e13372. PubMed ID: 34713962 [TBL] [Abstract][Full Text] [Related]
14. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review. Mathiesen DS; Bagger JI; Bergmann NC; Lund A; Christensen MB; Vilsbøll T; Knop FK Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443356 [TBL] [Abstract][Full Text] [Related]
15. Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates. Knerr PJ; Mowery SA; Finan B; Perez-Tilve D; Tschöp MH; DiMarchi RD Peptides; 2020 Mar; 125():170225. PubMed ID: 31786282 [TBL] [Abstract][Full Text] [Related]
16. An update on peptide-based therapies for type 2 diabetes and obesity. Bailey CJ; Flatt PR; Conlon JM Peptides; 2023 Mar; 161():170939. PubMed ID: 36608818 [TBL] [Abstract][Full Text] [Related]
17. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Samms RJ; Coghlan MP; Sloop KW Trends Endocrinol Metab; 2020 Jun; 31(6):410-421. PubMed ID: 32396843 [TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide. Nauck MA; Mirna AEA; Quast DR Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380 [TBL] [Abstract][Full Text] [Related]
19. Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity. Zaffina I; Pelle MC; Armentaro G; Giofrè F; Cassano V; Sciacqua A; Arturi F Front Endocrinol (Lausanne); 2023; 14():1095753. PubMed ID: 36909312 [TBL] [Abstract][Full Text] [Related]
20. New insights into the treatment of obesity. Blüher M; Aras M; Aronne LJ; Batterham RL; Giorgino F; Ji L; Pietiläinen KH; Schnell O; Tonchevska E; Wilding JPH Diabetes Obes Metab; 2023 Aug; 25(8):2058-2072. PubMed ID: 37055715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]